Αποτελέσματα Αναζήτησης
The mean dose of procainamide was 1207 ± 487 mg/day. Procainamide therapy significantly decreased ICD interventions (median 5 [0–22.5] vs 15.5 [3–32.25], P < .05). Procainamide also decreased the total number of VT/VF episodes (median 5.5 [0.75–30] vs 19 [7.5–30], P < .05). Only 3 patients (8.8%) presented severe side effects (dyspnea ...
8 Μαΐ 2023 · Monitoring. Procainamide monitoring during therapy of an acute arrhythmia should involve monitoring QRS duration via cardiac monitoring, and the clinician should stop therapy QRS increases by 50% of its original width. Also, blood pressure requires frequent monitoring during treatment.
For monomorphic ventricular tachycardia with a pulse or polymorphic ventricular tachycardia with a pulse (not due to torsades de pointes), administer procainamide at 1-2 grams over 5-60 minutes. See the dosage table above for further details.
3 Σεπ 2024 · Loading dose: 15 mg/kg infused intravenously over 30 to 60 minutes; monitor ECG and blood pressure; stop the infusion if hypotension occurs or QRS complex widens by more than 50% of baseline. Renal Dose Adjustments. Oral: CrCl less than 10 mL/min: A dosing interval of every 8 to 24 hours is recommended.
procainamide might represent an alternative strategy for pre-venting the recurrence of ventricular tachyarrhythmias and ICD discharges. Procainamide is a class 1a antiarrhythmic agent whose primary mechanism is related to its antagonism of cardiac sodium channels delaying phase 0 of the cardiac cycle. Procainamide and its metabolite N-acetyl ...
When procainamide is given in a hospital setting, it is typically given either intravenously or intramuscularly. When given intravenously, the patient’s ECG, blood pressure, and pulse should be...
Procainamide was more effective by 1.5 hours in those with AF than AFL/both: 46.3% vs 22.2% (P<0.01). All predictors except dose were associated with higher adjusted odds of cardioversion by 1.5 hours (Table).
